<DOC>
	<DOCNO>NCT00600808</DOCNO>
	<brief_summary>Annualised height velocity 12/24 month treatment HV SDS height velocity 12/24 month treatment express number standard deviation difference mean population height velocity appropriate gender chronological age .</brief_summary>
	<brief_title>Sustained Release Formulation Somatropin ( rDNA Origin ) Injection</brief_title>
	<detailed_description>To evaluate safety , efficacy pharmacokinetics/ pharmacodynamics LB03002 treatment growth failure child growth hormone deficiency ( GHD ) determine dose subsequent phase IIIb BPLG-004 study</detailed_description>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>Confirmed diagnosis GHD determine two different GH provocation test document deficient GH secretion , define peak plasma GH level le 7 ng/mL absence peak plasma GH level spontaneous growth hormone secretion 7 ng/mL monitor 3 hour application pharmacological stimulus least one stimulation test . Prepubertal child ( boys age : 410 year girl : age 49 year ) primary ( idiopathic ) secondary ( organic ) insufficiency growth hormone secretion . Children negative sign intracranial tumour tumour growth confirm Computer tomography ( CT ) magnetic resonance imaging ( MRI ) scan within 12 month prior inclusion within 6 month prior inclusion child GH insufficiency occur treatment brain tumour . Such patient least 24 month full clinical remission . No prior exposure rhGH ( GHnaïve ) Height ( HT ) least 2.0 standard deviation ( SD ) ( HT SDS ≤2.0 ) mean height chronological age ( CA ) sex accord Standards Prader et al15 . Height Velocity ( HV ) least 1 SD ( HV SDS ≤1 ) mean HV CA sex accord Standards Prader et al15 . Baseline IGFI level standardize age sex le 1.0 SDS Bone age ( BA ) ≤9 year boys ≤ 8 year girl , For child multiple hormonal deficiency , stabilize replacement therapy pituitary ax ( e.g . thyroidstimulating hormone , adrenocorticotropic hormone/cortisol vasopressin ) least 3 month 6 month thyroid replacement therapy prior enrolment child multiple hormonal deficiency . Written inform consent parent legal guardian subject . The result 3 hour spontaneous GH peak equal , 7 ng/ml . The value peak GH level case repeat pharmacology test 7 ng/ml , whilst 6 hour spontaneous peak GH value , Any clinically significant abnormality likely affect growth ability evaluate growth , , limit chronic disease like renal insufficiency , diabetes mellitus malnutrition ( BMI must 2SD +2SD mean BMI chronological age sex , albumin must lower limit normal ( LLN ) central laboratory patient include ) , Chromosomal abnormalities medical `` syndrome '' , exception holoprosencephaly/septooptic dysplasia ( Turner 's syndrome , Laron syndrome , Noonan syndrome absence growth hormone receptor ) . Congenital abnormality ( cause skeletal abnormality ) , RussellSilver Syndrome , Skeletal dysplasia , Closed epiphysis , Other growth promote medication anabolic steroid , exception pituitary hormone replacement therapy , thyroxine , hydrocortisone desmopressin ( DDAVP ) replacement therapy , Children require glucocorticoid therapy ( e.g . asthma ) dose 400 micro gram/day budesonide equivalent inhale longer 1 month year , Poorly control pituitary insufficiency ax ( e.g. , thyroidstimulating hormone , adrenocorticotropic hormone/cortisol , vasopressindeficiency ) , Major medical condition and/or presence contraindication rhGH treatment . Known suspected HIVpositive patient patient advance disease AIDS tuberculosis , Drug , substance , alcohol abuse , Known hypersensitivity component study medication , Evidence tumour growth malignant disease remission less one year At screening , presence antihGH antibodies The patient and/or parent/legal guardian likely noncompliant respect study conduct .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>SR-hGH , Pharmacokinetics , Pharmacodynamics</keyword>
</DOC>